NCT04489797 - A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

August 28, 2020

Study Completion Date

August 28, 2020

Conditions

Infectious Disease

Interventions

DRUG

Acalabrutinib

Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.

DRUG

Rabeprazole

Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.

Trial Locations (1)

Research Site, Anaheim